Name	: Mr. MOHAN M			
PID No.	: MED111292909	Register On :	10/09/2022 8:57 AM	M
SID No.	: 222016034	Collection On :	10/09/2022 9:03 AM	
Age / Sex	: 40 Year(s) / Male	Report On :	10/09/2022 6:45 PM	MEDALL
Туре	: OP	Printed On :	15/09/2022 3:50 PM	
Ref. Dr	: MediWheel			
Investigation		<u>Observed</u> <u>Value</u>	<u>Unit</u>	Biological Reference Interval
TYPING		'A' 'Positive'		
	ood/Agglutination)	noun and Tuning hafe	no blood transfusion	
	RETATION: Reconfirm the Blood g e Blood Count With - ESR	roup and Typing belo	re blood transfusion	
<u>compten</u>	<u> </u>			
Haemog (EDTA Ble	lobin ood/Spectrophotometry)	14.4	g/dL	13.5 - 18.0
	Cell Volume(PCV)/Haematocrit	43.0	%	42 - 52
RBC Cor (EDTA Blo	unt ood/Impedance Variation)	5.03	mill/cu.mm	4.7 - 6.0
	orpuscular Volume(MCV)	85.4	fL	78 - 100
	orpuscular Haemoglobin(MCH)	28.6	pg	27 - 32
concentra	orpuscular Haemoglobin ation(MCHC) ood/Derived from Impedance)	33.5	g/dL	32 - 36
RDW-C		13.5	%	11.5 - 16.0
RDW-SI		40.3	fL	39 - 46
	ukocyte Count (TC)	6600	cells/cu.mm	4000 - 11000
Neutroph (EDTA Blo <i>Cytometry</i>)	ood/Impedance Variation & Flow	57.2	%	40 - 75
Lymphoe (EDTA Blo <i>Cytometry</i>)	ood/Impedance Variation & Flow	31.2	%	20 - 45
Eosinoph (EDTA Blo Cytometry)	ood/Impedance Variation & Flow	4.7	%	01 - 06



VERIFIED BY



APPROVED BY

The results pertain to sample tested.

Page 1 of 7

Name	: Mr. MOHAN M	
PID No.	: MED111292909	Register On : 10/09/2022 8:57 AM
SID No.	: 222016034	Collection On : 10/09/2022 9:03 AM
Age / Sex	: 40 Year(s) / Male	Report On : 10/09/2022 6:45 PM
Туре	: OP	Printed On : 15/09/2022 3:50 PM
Ref. Dr	: MediWheel	

Investigation	<u>Observed</u> <u>Value</u>	<u>Unit</u>	Biological Reference Interval
Monocytes (EDTA Blood/Impedance Variation & Flow Cytometry)	6.0	%	01 - 10
Basophils (EDTA Blood'Impedance Variation & Flow Cytometry)	0.9	%	00 - 02
INTERPRETATION: Tests done on Automated	Five Part cell coun	ter. All abnormal results	are reviewed and confirmed microscopically.
Absolute Neutrophil count (EDTA Blood'Impedance Variation & Flow Cytometry)	3.8	10^3 / µl	1.5 - 6.6
Absolute Lymphocyte Count (EDTA Blood'Impedance Variation & Flow Cytometry)	2.0	10^3 / µl	1.5 - 3.5
Absolute Eosinophil Count (AEC) (EDTA Blood'Impedance Variation & Flow Cytometry)	0.3	10^3 / µl	0.04 - 0.44
Absolute Monocyte Count (EDTA Blood'Impedance Variation & Flow Cytometry)	0.4	10^3 / µl	< 1.0
Absolute Basophil count (EDTA Blood'Impedance Variation & Flow Cytometry)	0.1	10^3 / µl	< 0.2
Platelet Count (EDTA Blood'Impedance Variation)	264	10^3 / µl	150 - 450
MPV (EDTA Blood/Derived from Impedance)	8.3	fL	7.9 - 13.7
PCT (EDTA Blood/Automated Blood cell Counter)	0.220	%	0.18 - 0.28
ESR (Erythrocyte Sedimentation Rate) (Blood/Automated - Westergren method)	5	mm/hr	< 15
BUN / Creatinine Ratio	9.51		6.0 - 22.0
Glucose Fasting (FBS) (Plasma - F/ <i>GOD-PAP</i>)	90.5	mg/dL	Normal: < 100 Pre Diabetic: 100 - 125



Consultant Pathologist Reg No : 73347 10 Dr.

Diabetic: >= 126

APPROVED BY

MEDALL

The results pertain to sample tested.

Page 2 of 7

Name	: Mr. MOHAN M			
PID No.	MED111292909	Register On : 10	/09/2022 8:57 AM	C
SID No.	222016034	Collection On : 10	0/09/2022 9:03 AM	
Age / Sex :	40 Year(s) / Male	Report On : 1	0/09/2022 6:45 PM	MEDALL
Туре :	: OP	Printed On : 1	5/09/2022 3:50 PM	
Ref. Dr	: MediWheel			
Investigati	ion	<u>Observed</u> <u>Value</u>	Unit	Biological Reference Interval
INTERPRE blood glucos		uantity and time of food	intake, Physical activity	, Psychological stress, and drugs can influence
Glucose, F (Urine - F/Ge	Fasting (Urine) <i>OD - POD</i>)	Negative		Negative
Glucose Po (Plasma - PP	ostprandial (PPBS) P/GOD-PAP)	108.5	mg/dL	70 - 140
Fasting bloo	n as type, quantity and time of food od glucose level may be higher than	Postprandial glucose, b	ecause of physiological	nd drugs can influence blood glucose level. surge in Postprandial Insulin secretion, Insulin cation during treatment for Diabetes.
	cose(PP-2 hours)	Negative		Negative
(Urine - PP)				
	ea Nitrogen (BUN) ase UV / derived)	7.9	mg/dL	7.0 - 21
Creatinine		0.83	mg/dL	0.9 - 1.3
ingestion of	ETATION: Elevated Creatinine val cooked meat, consuming Protein/	Creatine supplements, D giotensin II receptor an	Diabetic Ketoacidosis, pro tagonists,N-acetylcysteir	evere dehydration, Pre-eclampsia, increased blonged fasting, renal dysfunction and drugs he, chemotherapeutic agent such as flucytosine
Uric Acid (Serum/Enzy		4.9	mg/dL	3.5 - 7.2
<u>Liver Fun</u>	ection Test			
Bilirubin(] (Serum/DCA		1.04	mg/dL	0.1 - 1.2
Bilirubin(I (Serum/Diaz	Direct) otized Sulfanilic Acid)	0.26	mg/dL	0.0 - 0.3
Bilirubin(I (Serum/Deri	· · · · · · · · · · · · · · · · · · ·	0.78	mg/dL	0.1 - 1.0
SGOT/AS Aminotran (Serum/Mod		25.4	U/L	5 - 40
SGPT/AL' (Serum/Modi	T (Alanine Aminotransferase) <i>ified IFCC</i>)	24.7	U/L	5 - 41





APPROVED BY

The results pertain to sample tested.


Page 3 of 7

Name	: Mr. MOHAN M			
PID No.	: MED111292909	Register On	: 10/09/2022 8:57 AM	
SID No.	: 222016034	Collection On	: 10/09/2022 9:03 AM	
Age / Sex	: 40 Year(s) / Male	Report On	: 10/09/2022 6:45 PM	MED
Туре	: OP	Printed On	: 15/09/2022 3:50 PM	
Ref. Dr	: MediWheel			

Investigation	<u>Observed</u> <u>Value</u>	Unit	<u>Biological</u> Reference Interval
GGT(Gamma Glutamyl Transpeptidase) (Serum/IFCC / Kinetic)	14.8	U/L	< 55
Alkaline Phosphatase (SAP) (Serum/ <i>Modified IFCC</i>)	73.7	U/L	53 - 128
Total Protein (Serum/Biuret)	6.93	gm/dl	6.0 - 8.0
Albumin (Serum/Bromocresol green)	4.23	gm/dl	3.5 - 5.2
Globulin (Serum/Derived)	2.70	gm/dL	2.3 - 3.6
A : G RATIO (Serum/Derived)	1.57		1.1 - 2.2
Lipid Profile			
Cholesterol Total (Serum/CHOD-PAP with ATCS)	211.4	mg/dL	Optimal: < 200 Borderline: 200 - 239 High Risk: >= 240
Triglycerides (Serum/GPO-PAP with ATCS)	63.7	mg/dL	Optimal: < 150 Borderline: 150 - 199 High: 200 - 499 Very High: >= 500

INTERPRETATION: The reference ranges are based on fasting condition. Triglyceride levels change drastically in response to food, increasing as much as 5 to 10 times the fasting levels, just a few hours after eating. Fasting triglyceride levels show considerable diurnal variation too. There is evidence recommending triglycerides estimation in non-fasting condition for evaluating the risk of heart disease and screening for metabolic syndrome, as non-fasting sample is more representative of the õusualö" circulating level of triglycerides during most part of the day.

HDL Cholesterol	47.3	mg/dL	Optimal(Negative Risk Factor): >=
(Serum/Immunoinhibition)			60





D(Path) sultant Pathologist Reg No : 73347 CO

APPROVED BY

The results pertain to sample tested.

Page 4 of 7

Name	: Mr. MOHAN M		
PID No.	: MED111292909	Register On : 10/09/2022 8:57 AM	C
SID No.	: 222016034	Collection On : 10/09/2022 9:03 AM	
Age / Sex	: 40 Year(s) / Male	Report On : 10/09/2022 6:45 PM	MEDALL
Туре	: OP	Printed On : 15/09/2022 3:50 PM	
Ref. Dr	: MediWheel		

Investigation	<u>Observed</u> <u>Value</u>	<u>Unit</u>	Biological Reference Interval
LDL Cholesterol (Serum/ <i>Calculated</i>)	151.4	mg/dL	Optimal: < 100 Above Optimal: 100 - 129 Borderline: 130 - 159 High: 160 - 189 Very High: >=190
VLDL Cholesterol (Serum/Calculated)	12.7	mg/dL	< 30
Non HDL Cholesterol (Serum/ <i>Calculated</i>)	164.1	mg/dL	Optimal: < 130 Above Optimal: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very High: >= 220

INTERPRETATION: 1.Non-HDL Cholesterol is now proven to be a better cardiovascular risk marker than LDL Cholesterol. 2.It is the sum of all potentially atherogenic proteins including LDL, IDL, VLDL and chylomicrons and it is the "new bad cholesterol" and is a co-primary target for cholesterol lowering therapy.

Total Cholesterol/HDL Cholesterol Ratio (Serum/ <i>Calculated</i>)	4.5		Optimal: < 3.3 Low Risk: 3.4 - 4.4 Average Risk: 4.5 - 7.1 Moderate Risk: 7.2 - 11.0 High Risk: > 11.0
Triglyceride/HDL Cholesterol Ratio (TG/HDL) (Serum/ <i>Calculated</i>)	1.3		Optimal: < 2.5 Mild to moderate risk: 2.5 - 5.0 High Risk: > 5.0
LDL/HDL Cholesterol Ratio (Serum/Calculated)	3.2		Optimal: 0.5 - 3.0 Borderline: 3.1 - 6.0 High Risk: > 6.0
<u>Glycosylated Haemoglobin (HbA1c)</u>			
HbA1C (Whole Blood/ <i>HPLC</i>)	5.6	%	Normal: 4.5 - 5.6 Prediabetes: 5.7 - 6.4 Diabetic: >= 6.5

INTERPRETATION: If Diabetes - Good control : 6.1 - 7.0 %, Fair control : 7.1 - 8.0 %, Poor control >= 8.1 %



I.D(Path) sultant Pathologist Reg No : 73347

APPROVED BY

The results pertain to sample tested.

Page 5 of 7

Name	: Mr. MOHAN M			
PID No.	: MED111292909	Register On :	10/09/2022 8:57 AM	m
SID No.	: 222016034	Collection On :	10/09/2022 9:03 AM	
Age / Sex	: 40 Year(s) / Male	Report On :	10/09/2022 6:45 PM	MEDALL
Туре	: OP	Printed On :	15/09/2022 3:50 PM	
Ref. Dr	: MediWheel	•		
<u>Investiga</u>	ition	<u>Observed</u> <u>Value</u>	Unit	Biological Reference Interval
Estimated (Whole Blo	d Average Glucose	114.02	mg/dL	
HbA1c pro control as Conditions hypertrigly Conditions	compared to blood and urinary gluco that prolong RBC life span like Iron cceridemia,hyperbilirubinemia,Drugs	ose determinations. n deficiency anemia, s, Alcohol, Lead Pois e or chronic blood los	Vitamin B12 & Folate de oning, Asplenia can give ss, hemolytic anemia, He	
	specific antigen - Total(PSA) nometric method)	1.11	ng/mL	Normal: 0.0 - 4.0 Inflammatory & Non Malignant conditions of Prostate & genitourinary system: 4.01 - 10.0 Suspicious of Malignant disease of Prostate: > 10.0
<u>THYROI</u> T3 (Triio	RETATION: REMARK : PSA alone (D PROFILE / TFT dothyronine) - Total	should not be used a 1.12	s an absolute indicator of ng/ml	f malignancy. 0.7 - 2.04
(CLIA))	emiluminescent Immunometric Assay RETATION: :			
	ariation can be seen in other condition	n like pregnancy, dru	igs, nephrosis etc. In sucl	h cases, Free T3 is recommended as it is
	xine) - Total emiluminescent Immunometric Assay	8.75	µg/dl	4.2 - 12.0
Comment	ariation can be seen in other condition	n like pregnancy, dru	ıgs, nephrosis etc. In sucl	h cases, Free T4 is recommended as it is
TSH (Th	yroid Stimulating Hormone) emiluminescent Immunometric Assay	1.34	µIU/mL	0.35 - 5.50
	SURUPRIDA J THOLOGIST No : 13-48036			Dr.E.Saravanan M.D.(Path) Consultant Pathologist Reg No : 73347
VE	RIFIED BY			APPROVED BY

The results pertain to sample tested.

Page 6 of 7

Name	: Mr. MOHAN M		
PID No.	: MED111292909	Register On : 10/09/2022 8:57 AM	\mathbf{C}
SID No.	: 222016034	Collection On : 10/09/2022 9:03 AM	-
Age / Sex	: 40 Year(s) / Male	Report On : 10/09/2022 6:45 PM	MEDALL
Туре	: OP	Printed On : 15/09/2022 3:50 PM	
Ref. Dr	: MediWheel		

Investigation Observed <u>Unit</u> **Biological** Value **Reference Interval INTERPRETATION:**

Reference range for cord blood - upto 20 1 st trimester: 0.1-2.5 2 nd trimester 0.2-3.0 3 rd trimester : 0.3-3.0 (Indian Thyroid Society Guidelines) **Comment :**

1.TSH reference range during pregnancy depends on Iodine intake, TPO status, Serum HCG concentration, race, Ethnicity and BMI. 2.TSH Levels are subject to circadian variation, reaching peak levels between 2-4am and at a minimum between 6-10PM. The variation can be of the order of 50%, hence time of the day has influence on the measured serum TSH concentrations.

3.Values&lt(0.03 µIU/mL need to be clinically correlated due to presence of rare TSH variant in some individuals.

Urine Analysis - Routine

COLOUR	Pale yellow		Yellow to Amber
(Urine) APPEARANCE (Urine)	Clear		Clear
Protein (Urine/Protein error of indicator)	Negative		Negative
Glucose (Urine/GOD - POD)	Negative		Negative
Pus Cells (Urine/Automated 6"Flow cytometry)	1 - 2	/hpf	NIL
Epithelial Cells (Urine/Automated of Flow cytometry)	Occasional	/hpf	NIL
RBCs (Urine/Automated 6"Flow cytometry)	NIL	/hpf	NIL
Casts (Urine/Automated 6"Flow cytometry)	NIL	/hpf	NIL
Crystals (Urine/Automated 6"Flow cytometry)	NIL	/hpf	NIL
Others (Urine)	NIL		

INTERPRETATION: Note: Done with Automated Urine Analyser & Automated urine sedimentation analyser. All abnormal reports are reviewed and confirmed microscopically.





APPROVED BY

-- End of Report --

The results pertain to sample tested.

Page 7 of 7